AIM•benzinga•
AIM ImmunoTech shares are trading higher after the company announced the publication of Phase 1 data from its Roswell Park study on Ampligen in early-stage triple-negative breast cancer.
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on November 19, 2024 by benzinga